Breast Cancer

, Volume 6, Issue 4, pp 361–364 | Cite as

Plasma nucleosome levels in node-negative breast cancer patients

  • Katsumasa Kuroi
  • Chikako Tanaka
  • Masakazu Toi
Panel Discussion III

Abstract

Background

A nucleosome is a primary repeating unit of organized DNA in chromatin, and cell death may lead to increased levels of circulating nucleosomes in plasma (PNLs) in various circumstances such as inflammation, pulmonary embolism, autoimmune disease and cancer.

Materials and Methods

We investigated PNLs in 96 patients with stage 0–III breast cancer (nodenegative, n=57; node-positive, n=39), and in 111 women without any evidence of disease as healthy controls. PNLs were detected using the Cell Death Detection ELISAplus kit (Boehringer Mannheim, Japan).

Results

The PNLs in normal controls were 0.010±0.012 units (mean±SD), while PNLs were significantly higher in both node-negative breast cancer (0.153±0.242) and node-positive breast cancer patients (0.116±0.172) (p<0.01). When PNLs were classified as high (>0.10) and low (≤0.l0), no correlation was found between high PNLs and clinicopathological factors such as tumor size, menopausal status, estrogen receptor status, histological type and lymphatic or venous spread in node-negative breast cancer. The relapse-free survival of patients with high PNLs tended to be better than those with low PNLs in both node-negative and node-positive breast cancer.

Conclusion

Increased PNLs were found in breast cancer patients, and PNLs seem promising as a new prognostic factor for both node-negative and node-positive breast cancer.

Key words

Nucleosome Breast cancer Apoptosis Prognostic factor 

Abbreviations

PNLs

Plasma nucleosome levels

RFS

Relapse-free survival

ELISA

Enzyme-linked immunosorbent assay

NK

Natural killer

Al

Apoptotic index

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1).
    Fournie GJ: Circulating DNA and lupus nephritis.Kidney Int 33:487–497, 1988.PubMedCrossRefGoogle Scholar
  2. 2).
    Leon SA, Shapiro B, Sklaroff DM,et al: Free DNA in the serum of cancer patients and the effect of therapy.Cancer Res 37:646–650, 1977.PubMedGoogle Scholar
  3. 3).
    Shapiro B, Chakrabarty M, Cohn EM,et al: Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease.Cancer 51:2116–2120, 1983.PubMedCrossRefGoogle Scholar
  4. 4).
    Stroun M, Anker P, Lyautey J,et al: Isolation and characterization of DNA from the plasma of cancer patients.Eur J Cancer Oncol 23:707–712, 1987.CrossRefGoogle Scholar
  5. 5).
    Giacona MB, Ruben GC, Iczkowski KA,et al: Cellfree DNA in human blood plasma; Length measurements in patients with pancreatic cancer and healthy controls.Pancreas 17:89–97, 1998.PubMedCrossRefGoogle Scholar
  6. 6).
    Vasioukhin V, Anker P, Maurice P,et al: Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogeneous leukaemia.Br J Haematol 86:774–779, 1994.PubMedCrossRefGoogle Scholar
  7. 7).
    Chen YQ, Stroun M, Magnenat JL,et al: Micro satellite alterations in plasma DNA of small cell lung cancer patients.Nat Med 9:1033–1034, 1996.CrossRefGoogle Scholar
  8. 8).
    Nawroz H, Koch W, Anker P,et al: Microsatellite alterations in serum DNA of head and neck cancer patients.Nat Med 9:1035–1037, 1996.CrossRefGoogle Scholar
  9. 9).
    Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer, 12th ed, Kanehara, Tokyo, ppl-56, 1996.Google Scholar
  10. 10).
    Le Lann AD, Fournie GJ, Boissier L,et al: In vitro inhibition of natural-killer-mediated lysis by chromatin fragments.Cancer Immunol Immunother 39:185–192, 1994.Google Scholar
  11. 11).
    Kajiwara M, Toyoshima S, Yao T,et al: Apoptosis and cell proliferation in medullary carcinoma of the breast; A comparative study between medullary and non-medullary carcinoma using the TUNEL method and immunohistochemistry.J Surg Oncol 70:209–216, 1999.PubMedCrossRefGoogle Scholar
  12. 12).
    Kerr JFR, Winterford CM: Apoptosis; Its significance in cancer and cancer therapy.Cancer 73:2013–2026, 1994.PubMedCrossRefGoogle Scholar
  13. 13).
    Thompson C: Apoptosis in the pathogenesis and treatment of disease.Science 267:1456–1462, 1995.PubMedCrossRefGoogle Scholar
  14. 14).
    Shao AM, Jiang M, Wu J,et al: Identification of spontaneous programmed cell death during development of human breast cancer.Oncology Rep 3:1133–1136, 1996.Google Scholar
  15. 15).
    Lipponen P, Aaltomaa S, Kosma VM,et al: Apoptosis in breast cancer as related to histopathological characteristics and prognosis.Eur J Cancer 30:2068–2073, 1994.CrossRefGoogle Scholar
  16. 16).
    Zhang GJ, Kimijima I, Abe R,et al: Apopototic index correlates to bcl-2 and p-53 protein expression, histological grade and prognosis in invasive breast cancers.Anticancer Res 18:1989–1998, 1998.PubMedGoogle Scholar
  17. 17).
    Vakkala M, Lahteenmaki K, Raunio H,et al: Apoptosis during breast carcinoma progression.Clin Cancer Res 5:319–324, 1999.PubMedGoogle Scholar
  18. 18).
    Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.J Cell Biol 119:493–501, 1992.PubMedCrossRefGoogle Scholar
  19. 19).
    Leon SA, Shapiro B, Servei P,et al: A comparison of DNA and DNA-binding protein levels in malignant disease.Eur J Cancer 17:533–538, 1981.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 1999

Authors and Affiliations

  • Katsumasa Kuroi
    • 1
  • Chikako Tanaka
    • 1
  • Masakazu Toi
    • 1
  1. 1.Department of SurgeryTokyo Metropolitan Komagome HospitalTokyo

Personalised recommendations